Molecular analysis of RET proto-oncogene in patients with medullary thyroid carcinoma
Introduction: Medullary Thyroid Carcinoma (MTC) accounts for 5-10% of thyroid cancers
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Introduction: Medullary Thyroid Carcinoma (MTC) accounts for 5-10% of thyroid cancers
ABSTRACT: 18 year female presented with right side solitary thyroid nodule measuring
rarity has been increasingly observed. The pathogenesis is still controversial. Genetic analysis of RET proto-oncogenes in cases of simultaneous papillary thyroid carcinoma and medullary thyroid carcinoma
some sporadic forms of the disease are characterized by a mutation of the proto-oncogene RET. This results in an abnormal growth factor receptor that, in turn, allows the malignant
MEN2A) is an autosomal dominant syndrome associated with germline mutations in the RET proto-oncogene that may lead to medullary thyroid carcinomas (MTC), pheochromocytomas, and parathyroid adenomas. Patients generally…
affects the parathyroid, pancreas, and pituitary glands. MEN2, caused by mutations in the RET proto-oncogene, is further classified into MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC), with medullary
mutations involving the tyrosine kinase or mTOR pathway, the MEN1 gene and the ret proto-oncogene and the recent recognition of DAXX and ATRX genes associated with chromatin remodeling. There
they have not been confirmed. Moreover, genetic components-for example proto-oncogenes, which encode Receptor Tyrosine Kinases (RET) and small GT Pases (RAS)-may contribute to thyroid cancer formation
they have not been confirmed. Moreover, genetic components-for example proto-oncogenes, which encode receptor tyrosine kinases (RET) and small GT Pases (RAS)-may contribute to thyroid cancer formation
For authors and organisers
Find the right journal for your paper and submit your manuscript.